{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:54:58Z","timestamp":1790470498295,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s10741-018-9698-8","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:43Z","timestamp":1522800043000},"page":"631-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-5152","authenticated-orcid":false,"given":"Marijana","family":"Tadic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Cuspidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Frydas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"issue":"27","key":"9698_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) Authors\/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association(HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"key":"9698_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14:591\u2013602","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"9698_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","volume":"63","author":"AP Ambrosy","year":"2014","unstructured":"Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123\u20131133","journal-title":"J Am Coll Cardiol"},{"key":"9698_CR4","doi-asserted-by":"publisher","unstructured":"Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Cameron VA, Poppe K, Lund M, Devlin G, Troughton R, Richards AM, Doughty RN. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018 Jan 29. doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehy005 .","DOI":"10.1093\/eurheartj\/ehy005"},{"issue":"2","key":"9698_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","volume":"10","author":"JJ McMurray","year":"2008","unstructured":"McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM (2008) Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 10(2):149\u2013156","journal-title":"Eur J Heart Fail"},{"issue":"5\u20136","key":"9698_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1089\/ars.2006.8.691","volume":"8","author":"AC Cave","year":"2006","unstructured":"Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8(5\u20136):691\u2013728","journal-title":"Antioxid Redox Signal"},{"key":"9698_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/825027","volume":"2015","author":"SI Negi","year":"2015","unstructured":"Negi SI, Jeong EM, Shukrullah I, Veleder E, Jones DP, Fan TH, Varadarajan S, Danilov SM, Fukai T, Dudley SC Jr (2015) Renin-angiotensin activation and oxidative stress in early heart failure with preserved ejection fraction. Biomed Res Int 2015:825027","journal-title":"Biomed Res Int"},{"issue":"4","key":"9698_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ehf2.12204","volume":"4","author":"MS Khan","year":"2017","unstructured":"Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheorghiade M, Butler J (2017) Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 4(4):402\u2013408","journal-title":"ESC Heart Fail."},{"issue":"6","key":"9698_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10741-017-9637-0","volume":"22","author":"H Fukuta","year":"2017","unstructured":"Fukuta H, Goto T, Wakami K, Ohte N (2017) Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Heart Fail Rev 22(6):775\u2013782","journal-title":"Heart Fail Rev"},{"issue":"2","key":"9698_CR10","doi-asserted-by":"publisher","first-page":"e003588","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","volume":"10","author":"IE Beldhuis","year":"2017","unstructured":"Beldhuis IE, Streng KW, Ter Maaten JM, Voors AA, van der Meer P, Rossignol P, McMurray JJ, Damman K (2017) Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data. Circ Heart Fail. 10(2):e003588","journal-title":"Circ Heart Fail."},{"issue":"1","key":"9698_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/fca.12.75","volume":"9","author":"C Clarke","year":"2013","unstructured":"Clarke C, Flores-Mu\u00f1oz M, McKinney CA, Milligan G, Nicklin SA (2013) Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensinsystem. Futur Cardiol 9(1):23\u201338","journal-title":"Futur Cardiol"},{"issue":"13","key":"9698_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1055\/s-0035-1565055","volume":"47","author":"C Catena","year":"2015","unstructured":"Catena C, Colussi G, Brosolo G, Novello M, Sechi LA (2015) Aldosterone and left ventricular remodeling. Horm Metab Res 47(13):981\u2013986","journal-title":"Horm Metab Res"},{"issue":"6","key":"9698_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"L Riet Te","year":"2015","unstructured":"Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH (2015) Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 116(6):960\u2013975","journal-title":"Circ Res"},{"key":"9698_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/689360","volume":"2014","author":"M Pacurari","year":"2014","unstructured":"Pacurari M, Kafoury R, Tchounwou PB, Ndebele K (2014) The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam 2014:689360","journal-title":"Int J Inflam"},{"issue":"4","key":"9698_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/10641963.2016.1267196","volume":"39","author":"E Bahramali","year":"2017","unstructured":"Bahramali E, Firouzabadi N, Rajabi M, Manafi A, Zarghami M, Mousavi SM, Jamshidi J (2017) Association of renin-angiotensin-aldosterone system gene polymorphisms with left ventricular hypertrophy in patients with heart failure with preserved ejection fraction: a case-control study. Clin Exp Hypertens 39(4):371\u2013376","journal-title":"Clin Exp Hypertens"},{"issue":"2","key":"9698_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117332","volume":"10","author":"WL Verloop","year":"2015","unstructured":"Verloop WL, Beeftink MM, Santema BT, Bots ML, Blankestijn PJ, Cramer MJ, Doevendans PA, Voskuil M (2015) A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction. PLoS One 10(2):e0117332","journal-title":"PLoS One"},{"issue":"2","key":"9698_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.108.121467","volume":"53","author":"G Grassi","year":"2009","unstructured":"Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Spaziani D, Mancia G (2009) Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 53(2):205\u2013209","journal-title":"Hypertension"},{"issue":"2","key":"9698_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2005.06.041","volume":"110","author":"G Piccirillo","year":"2006","unstructured":"Piccirillo G, German\u00f2 G, Vitarelli A, Ragazzo M, di Carlo S, De Laurentis T, Torrini A, Matera S, Magnanti M, Marchitto N, Bonanni L, Magr\u00ec D (2006) Autonomic cardiovascular control and diastolic dysfunction in hypertensive subjects. Int J Cardiol 110(2):160\u2013166","journal-title":"Int J Cardiol"},{"key":"9698_CR19","doi-asserted-by":"crossref","unstructured":"de Souza SB 1, Rocha JA, Cuoco MA, Guerra GM, Ferreira-Filho JC, Borile S, Krieger EM, Bortolotto LA, Consolim-Colombo FM. High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive patients. Am J Hypertens 2013 Jul;26(7):912\u2013917","DOI":"10.1093\/ajh\/hpt032"},{"issue":"2","key":"9698_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/HYPERTENSIONAHA.108.126177","volume":"53","author":"C Rosendorff","year":"2009","unstructured":"Rosendorff C (2009) The chicken and the egg: sympathetic nervous system activity and left ventricular diastolic dysfunction. Hypertension 53(2):108\u2013109","journal-title":"Hypertension"},{"issue":"1","key":"9698_CR21","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1097\/01.hjh.0000220407.84363.fb","volume":"24","author":"G Mancia","year":"2006","unstructured":"Mancia G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Grassi G (2006) Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl 24(1):S51\u2013S56","journal-title":"J Hypertens Suppl"},{"issue":"1","key":"9698_CR22","first-page":"1","volume":"12","author":"Z Szel\u00e9nyi","year":"2015","unstructured":"Szel\u00e9nyi Z, Fazakas \u00c1, Sz\u00e9n\u00e1si G, Kiss M, Tegze N, Fekete BC, Nagy E, Bod\u00f3 I, Nagy B, Molvarec A, Pat\u00f3cs A, Pep\u00f3 L, Proh\u00e1szka Z, Vereckei A (2015) Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. J Geriatr Cardiol 12(1):1\u201310","journal-title":"J Geriatr Cardiol"},{"issue":"10","key":"9698_CR23","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1152\/japplphysiol.00374.2015","volume":"119","author":"FR Heinzel","year":"2015","unstructured":"Heinzel FR, Hohendanner F, Jin G3, Sedej S, Edelmann F (2015) Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol (1985) 119(10):1233\u20131242","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"9698_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10741-017-9618-3","volume":"22","author":"M Tadic","year":"2017","unstructured":"Tadic M, Pieske-Kraigher E, Cuspidi C, Genger M, Morris DA, Zhang K, Walther NA, Pieske B (2017) Left ventricular strain and twisting in heart failure with preserved ejection fraction: an updated review. Heart Fail Rev 22(3):371\u2013379","journal-title":"Heart Fail Rev"},{"issue":"5","key":"9698_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/08037051.2014.907978","volume":"23","author":"M Tadic","year":"2014","unstructured":"Tadic M, Cuspidi C, Backovic S, Kleut M, Ivanovic B, Scepanovic R, Iracek O, Celic V (2014) High-normal blood pressure, functional capacity and left heart mechanics: is there any connection? Blood Press 23(5):315\u2013321","journal-title":"Blood Press"},{"issue":"8","key":"9698_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jcmg.2015.09.027","volume":"9","author":"M Saito","year":"2016","unstructured":"Saito M, Khan F, Stoklosa T, Iannaccone A, Negishi K, Marwick TH (2016) Prognostic implications of LV strain risk score in asymptomatic patients with hypertensive heart disease. JACC Cardiovasc Imaging 9(8):911\u2013921","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"9698_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ehf2.12159","volume":"4","author":"J Buggey","year":"2017","unstructured":"Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, Velazquez EJ (2017) Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Fail. 4(4):432\u2013439","journal-title":"ESC Heart Fail."},{"issue":"2","key":"9698_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.116.08327","volume":"69","author":"A Pandey","year":"2017","unstructured":"Pandey A, Khan H, Newman AB, Lakatta EG, Forman DE, Butler J, Berry JD (2017) Arterial stiffness and risk of overall heart failure, heart failure with preserved ejection fraction, and heart failure with reduced ejection fraction: the health ABC study (health, aging, and body composition). Hypertension 69(2):267\u2013274","journal-title":"Hypertension"},{"key":"9698_CR29","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam CSP, Lund LH (2017) A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 19:1624\u20131634","journal-title":"Eur J Heart Fail"},{"key":"9698_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2017.09.187","volume":"254","author":"TK Teng","year":"2018","unstructured":"Teng TK, Tay WT, Dahlstrom U, Benson L, Lam CSP, Lund LH (2018) Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 254:203\u2013209","journal-title":"Int J Cardiol"},{"issue":"8","key":"9698_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","volume":"5","author":"U Sartipy","year":"2017","unstructured":"Sartipy U, Dahlstr\u00f6m U, Fu M, Lund LH (2017) Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 5(8):565\u2013574","journal-title":"JACC Heart Fail"},{"key":"9698_CR32","doi-asserted-by":"publisher","unstructured":"Tsimploulis A, Lam PH, Arundel C, Singh SN, Morgan CJ, Faselis C, Deedwania P, Butler J, Aronow WS, Yancy CW, Fonarow GC, Ahmed A (2018) Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2017.5365 [Epub ahead of print]","DOI":"10.1001\/jamacardio.2017.5365"},{"key":"9698_CR33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jch.13210","volume":"20","author":"J Gu","year":"2018","unstructured":"Gu J, Fan YQ, Zhang HL, Zhang JF, Wang CQ (2018) Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. J Clin Hypertens (Greenwich) 20:560\u2013567. https:\/\/doi.org\/10.1111\/jch.13210 . [Epub ahead of print]","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"7","key":"9698_CR34","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.amjcard.2016.07.013","volume":"118","author":"H Okura","year":"2016","unstructured":"Okura H, Kataoka T, Yoshida K (2016) Comparison of left ventricular relaxation and left atrial function in patients with heart failure and preserved ejection fraction versus patients with systemic hypertension and healthy subjects. Am J Cardiol 118(7):1019\u20131023","journal-title":"Am J Cardiol"},{"issue":"19","key":"9698_CR35","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345","journal-title":"Eur Heart J"},{"issue":"4","key":"9698_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/CIRCHEARTFAILURE.109.898916","volume":"3","author":"DW Kitzman","year":"2010","unstructured":"Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, Little WC (2010) A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 3(4):477\u2013485","journal-title":"Circ Heart Fail"},{"key":"9698_CR37","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362(9386):777\u2013781","DOI":"10.1016\/S0140-6736(03)14285-7"},{"issue":"23","key":"9698_CR38","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, Investigators I-PRESERVE (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456\u20132467","journal-title":"N Engl J Med"},{"key":"9698_CR39","doi-asserted-by":"crossref","unstructured":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejectionfraction: a phase 2 double-blind randomised controlled trial. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. Lancet . 2012;380(9851):1387\u201395","DOI":"10.1016\/S0140-6736(12)61227-6"},{"issue":"15","key":"9698_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators TOPCAT (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"8","key":"9698_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, L\u00f6ffler M, D\u00fcngen HD, Tsch\u00f6pe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Investigators A-DHF (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8):781\u2013791","journal-title":"JAMA"},{"issue":"1","key":"9698_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","volume":"15","author":"K Yamamoto","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M, Investigators J-DHF (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15(1):110\u2013118","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"9698_CR43","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","volume":"53","author":"DJ Veldhuisen van","year":"2009","unstructured":"van Veldhuisen DJ, Cohen-Solal A, B\u00f6hm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, Investigators SENIORS (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (study of effects of Nebivolol intervention on outcomes and Rehospitalization in Seniors with heart failure). J Am Coll Cardiol 53(23):2150\u20132158","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"9698_CR44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2229-3485.210449","volume":"8","author":"N Mittal","year":"2017","unstructured":"Mittal N, Shafiq N, Reddy S, Malhotra S, Kumari S, Varma S (2017) Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: a randomized, double-blind, placebo-controlled pilot trial. Perspect Clin Res 8(3):124\u2013131","journal-title":"Perspect Clin Res"},{"issue":"6","key":"9698_CR45","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","volume":"7","author":"K Patel","year":"2014","unstructured":"Patel K, Fonarow GC, Ahmed M, Morgan C, Kilgore M, Love TE, Deedwania P, Aronow WS, Anker SD, Ahmed A (2014) Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. Circ Heart Fail 7(6):945\u2013952","journal-title":"Circ Heart Fail"},{"issue":"4","key":"9698_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/10641963.2016.1267198","volume":"39","author":"S Kiuchi","year":"2017","unstructured":"Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T (2017) Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction. Clin Exp Hypertens 39(4):350\u2013354","journal-title":"Clin Exp Hypertens"},{"issue":"12","key":"9698_CR47","first-page":"27","volume":"56","author":"SG Kanorskii","year":"2016","unstructured":"Kanorskii SG, Sereda AF (2016) Comparison of verapamil and amlodipine for treatment of chronic heart failure with preserved left ventricular ejection fraction in patients with hypertensive disease. Kardiologiia 56(12):27\u201332","journal-title":"Kardiologiia"},{"issue":"15","key":"9698_CR48","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","volume":"62","author":"W Kosmala","year":"2013","unstructured":"Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH (2013) Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62(15):1330\u20131338","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"9698_CR49","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","volume":"132","author":"N Pal","year":"2015","unstructured":"Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S, Dawson DK, Francis JM, Dwight JS, Watkins H, Neubauer S, Frenneaux M, Ashrafian H (2015) Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132(18):1719\u20131725","journal-title":"Circulation"},{"issue":"11","key":"9698_CR50","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, B\u00f6hm M (2017) prEserveD left ventricular ejectIon fraction chronic heart failure with ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19(11):1495\u20131503","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"9698_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","volume":"104","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO, Ayis S (2018) Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart 104(5):407\u2013415","journal-title":"Heart"},{"issue":"3","key":"9698_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.21037\/cdt.2017.03.04","volume":"7","author":"R Vecchis De","year":"2017","unstructured":"De Vecchis R, Ariano C (2017) Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials. Cardiovasc Diagn Ther 7(3):272\u2013287","journal-title":"Cardiovasc Diagn Ther"},{"key":"9698_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijcard.2016.11.239","volume":"228","author":"H Fukuta","year":"2017","unstructured":"Fukuta H, Goto T, Wakami K, Ohte N (2017) The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Int J Cardiol 228:4\u201310","journal-title":"Int J Cardiol"},{"issue":"5","key":"9698_CR54","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/hrt.2007.117978","volume":"94","author":"GW Yip","year":"2008","unstructured":"Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE (2008) The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 94(5):573\u2013580","journal-title":"Heart"},{"issue":"5","key":"9698_CR55","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCHEARTFAILURE.112.970061","volume":"5","author":"CS Lam","year":"2012","unstructured":"Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW (2012) Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circ Heart Fail. 5(5):571\u2013578","journal-title":"Circ Heart Fail."},{"issue":"10","key":"9698_CR56","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/eurjhf\/hfs101","volume":"14","author":"K Patel","year":"2012","unstructured":"Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A (2012) Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 14(10):1179\u20131188","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"9698_CR57","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail 17(8):634\u2013642","journal-title":"J Card Fail"},{"issue":"6","key":"9698_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ejhf.76","volume":"16","author":"PS Jhund","year":"2014","unstructured":"Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD (2014) Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 16(6):671\u2013677","journal-title":"Eur J Heart Fail"},{"key":"9698_CR59","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, B\u00f6hm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson \u00c5, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39(1):26\u201335","DOI":"10.1093\/eurheartj\/ehx564"},{"key":"9698_CR60","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijcard.2016.07.292","volume":"222","author":"G Ruiz","year":"2016","unstructured":"Ruiz G, Andrey JL, Puerto JL, Escobar MA, Romero SP, Aranda R, Pedrosa MJ, Gomez F (2016) Prognosis of heart failure with preserved ejection fraction treated with \u03b2-blockers: a propensity matched study in the community. Int J Cardiol 222:594\u2013602","journal-title":"Int J Cardiol"},{"issue":"13","key":"9698_CR61","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1177\/2047487316636260","volume":"23","author":"J Gu","year":"2016","unstructured":"Gu J, Fan YQ, Bian L, Zhang HL, Xu ZJ, Zhang Y, Chen QZ, Yin ZF, Xie YS, Wang CQ (2016 Sep) Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: a retrospective observational cohort study. Eur J Prev Cardiol 23(13):1421\u20131428","journal-title":"Eur J Prev Cardiol"},{"issue":"19","key":"9698_CR62","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2014.15241","volume":"312","author":"LH Lund","year":"2014","unstructured":"Lund LH, Benson L, Dahlstr\u00f6m U, Edner M, Friberg L (2014) Association between use of \u03b2-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312(19):2008\u20132018","journal-title":"JAMA"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-018-9698-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9698-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9698-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T14:26:50Z","timestamp":1720189610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-018-9698-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["9698"],"URL":"https:\/\/doi.org\/10.1007\/s10741-018-9698-8","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"4 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}